Cellzome licenses Episphere to GlaxoSmithKline
Executive Summary
Less than two years after receiving an option to Cellzome AG's anti-inflammatory kinase inhibitors, GlaxoSmithKline PLC is working with the chemical proteomics company again. This time the Big Pharma has received exclusive rights to Cellzome's Episphere epigenetics platform for development of immuno-inflammation therapeutics.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice